Pediatric hematopoietic stem cell transplantation (HSCT) is considered standard-of-care treatment for a number of malignant and nonmalignant conditions. Treatment generally involves exposure to chemotherapy and occasionally radiation to encourage engraftment of donor stem cells and prevent donor and recipient rejection.…
A major cause of mortality and morbidity after allogeneic hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GVHD) , which is caused by engraftment of immunocompetent donor T lymphocytes in an immunologically compromised host who shows histocompatibility differences with the…
Two thirds of patients who need allogeneic hematopoietic stem cell transplantation (HSCT) do not have an available HLA-identical sibling. Alternative sources of hematopoietic stem cells (HSCs) are being increasingly used and include matched unrelated donors, unrelated umbilical cord blood ,…
Allogeneic (from a donor) or autologous (from the same individual) hematopoietic stem cells have been used to cure both malignant and nonmalignant disorders. Autologous transplantation is employed as a rescue strategy after delivering otherwise lethal doses of chemotherapy with or…